Showing results (171-180 of 208) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|May 27, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022Claus Garbe, Teresa Amaral, Ketty Peris, et al.European Journal of Cancer (Oxford, England : 1990)|June 22, 2022
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022Marie-Léa Gauci, Cynthia Aristei, Jurgen C Becker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.European Journal of Cancer (Oxford, England : 1990)|May 15, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022Claus Garbe, Teresa Amaral, Ketty Peris, et al.The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.The Lancet. Oncology|September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.Lancet (London, England)|April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialJason J Luke, Piotr Rutkowski, Paola Queirolo, et al.The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.Pageof 21